Dr. Reddy’s signs multicountry deal with HK inno.N for Tegoprazan

Indian firm Dr. Reddy’s Laboratories has entered into an exclusive partnership with South Koreabased HK inno.N Corporation, for the supply and commercialisation of HK inno.N Corporation’s patented novel molecule Tegoprazan for gastrointestinal diseases in India and six key Emerging Markets. HK inno.N Corporation’s Tegoprazan induces fast onset of action and can control gastric pH for a prolonged period, potentially offering significant clinical benefit in acid-related disorders. Tegoprazan is already approved in South Korea and China, and is under registration and clinical development in several countries globally, including the USA. Under this partnership, HK inno.N Corporation will be responsible for the manufacture and supply of Tegoprazan, while Dr. Reddy’s will be responsible for local clinical development, registration, marketing and sales in the licensed territories. The agreement grants Dr. Reddy’s the exclusive rights to develop and commercialise Tegoprazan under its own trademark in these markets for 10 years from the first commercial launch. HK inno.N Corporation will receive an upfront licensing fee, and will be eligible for potential regulatory milestone payments and royalties on net product sales.